In translational studies, the clinical values of SH3BP1 serving as a novel WAVE2 regulator and a prognostic biomarker were evaluated to predict future metastasis and recurrence in HCC patients. This evidence concerns the gene SH3BP1 and hepatocellular carcinoma.